4.6 Article

Major depressive disorder

Journal

NATURE REVIEWS DISEASE PRIMERS
Volume 2, Issue -, Pages -

Publisher

NATURE PORTFOLIO
DOI: 10.1038/nrdp.2016.65

Keywords

-

Funding

  1. Jansen Research
  2. VICI grant from the Dutch Scientific Organization
  3. National Institute for Health Research Mental Health Biomedical Research Centre in Mental Health at South London, Maudsley NHS Foundation Trust and King's College London
  4. Medical Research Council (UK) [MR/J002739/1, MR/L014815/1]
  5. Wellcome Trust
  6. Johnson Johnson
  7. Lundbeck
  8. Brain Resource, Inc.
  9. Abbot Laboratories
  10. Alkermes, Inc.
  11. American Cyanamid
  12. Aspect Medical Systems
  13. AstraZeneca
  14. Avanir Pharmaceuticals
  15. BioResearch
  16. BrainCells Inc.
  17. Bristol-Myers Squibb
  18. CeNeRx BioPharma
  19. Cephalon
  20. Cerecor
  21. Clintara, LLC
  22. Covance
  23. Covidien
  24. Eli Lilly and Company
  25. EnVivo Pharmaceuticals, Inc.
  26. Euthymics Bioscience, Inc.
  27. Forest Pharmaceuticals, Inc.
  28. FORUM Pharmaceuticals
  29. Ganeden Biotech, Inc.
  30. GlaxoSmithKline
  31. Harvard Clinical Research Institute
  32. Hoffman-LaRoche
  33. Icon Clinical Research
  34. i3 Innovus/Ingenix
  35. Janssen RD, LLC
  36. Jed Foundation
  37. Johnson & Johnson Pharmaceutical Research Development
  38. Lichtwer Pharma GmbH
  39. Lorex Pharmaceuticals
  40. Lundbeck Inc.
  41. MedAvante
  42. Methylation Sciences Inc.
  43. National Alliance for Research on Schizophrenia & Depression (NARSAD)
  44. National Center for Complementary and Alternative Medicine (NCCAM)
  45. National Coordinating Center for Integrated Medicine (NiiCM)
  46. National Institute of Drug Abuse (NIDA)
  47. National Institute of Mental Health (NIMH)
  48. Neuralstem, Inc.
  49. Novartis AG
  50. Organon Pharmaceuticals
  51. PamLab, LLC.
  52. Pfizer Inc.
  53. Pharmacia-Upjohn
  54. Pharmaceutical Research Associates., Inc.
  55. Pharmavite(R) LLC
  56. PharmoRx Therapeutics
  57. Photothera
  58. Reckitt Benckiser
  59. Roche Pharmaceuticals
  60. RCT Logic, LLC
  61. Sanofi-Aventis US LLC
  62. Shire
  63. Solvay Pharmaceuticals, Inc.
  64. Stanley Medical Research Institute (SMRI)
  65. Synthelabo
  66. Takeda Pharmaceuticals
  67. Tal Medical
  68. Wyeth-Ayerst Laboratories
  69. Medical Research Council [MR/L014815/1, MR/N029488/1, G108/603] Funding Source: researchfish
  70. National Institute for Health Research [NF-SI-0513-10051] Funding Source: researchfish
  71. MRC [MR/N029488/1, G108/603, MR/L014815/1] Funding Source: UKRI

Ask authors/readers for more resources

Major depressive disorder (MDD) is a debilitating disease that is characterized by depressed mood, diminished interests, impaired cognitive function and vegetative symptoms, such as disturbed sleep or appetite. MDD occurs about twice as often in women than it does in men and affects one in six adults in their lifetime. The aetiology of MDD is multifactorial and its heritability is estimated to be approximately 35%. In addition, environmental factors, such as sexual, physical or emotional abuse during childhood, are strongly associated with the risk of developing MDD. No established mechanism can explain all aspects of the disease. However, MDD is associated with alterations in regional brain volumes, particularly the hippocampus, and with functional changes in brain circuits, such as the cognitive control network and the affective-salience network. Furthermore, disturbances in the main neurobiological stress-responsive systems, including the hypothalamic-pituitary-adrenal axis and the immune system, occur in MDD. Management primarily comprises psychotherapy and pharmacological treatment. For treatment-resistant patients who have not responded to several augmentation or combination treatment attempts, electroconvulsive therapy is the treatment with the best empirical evidence. In this Primer, we provide an overview of the current evidence of MDD, including its epidemiology, aetiology, pathophysiology, diagnosis and treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available